ESMO: Sanofi/Regeneron’s Latecomer Anti-PD-1 Libtayo Looking Likely In NSCLC

Libtayo Shows 32% OS Benefit In EMPOWER-Lung 1

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.